| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Cyclosporin B targets calcineurin, a protein phosphatase involved in T cell activation. By inhibiting calcineurin, it blocks the transcription of interleukin-2 and other cytokines, leading to immunosuppression. It also inhibits P-glycoprotein activity.
|
|---|---|
| ln Vitro |
Cyclosporin B inhibits the growth of T lymphoma cells in a concentration-dependent manner. It inhibits P-glycoprotein activity in vitro with an IC50 value of 4.7 μM. It is an immunosuppressant.
|
| ln Vivo |
Cyclosporin B has been used in organ transplantation and autoimmune diseases. It is structurally similar to cyclosporin A. It is a potent immunosuppressant.
|
| Enzyme Assay |
Cyclosporin B is evaluated in cell-free assays for its ability to inhibit calcineurin. The compound is incubated with calcineurin and a substrate, and the inhibition of enzyme activity is measured. P-glycoprotein activity is assessed using transport assays.
|
| Cell Assay |
Cyclosporin B is assessed in cell-based assays using T lymphoma cells. Cells are treated with Cyclosporin B, and cell growth and P-glycoprotein activity are measured.
|
| Animal Protocol |
Cyclosporin B is administered in animal models to evaluate its immunosuppressive effects. It has been used in organ transplantation studies.
|
| ADME/Pharmacokinetics |
Cyclosporin B has a molecular weight of 1188.59 and a molecular formula of C61H109N11O12. It has a CAS number of 63775-95-1. The compound is soluble in ethanol, methanol, DMF, and DMSO; it has limited water solubility.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is available for Cyclosporin B beyond its known use as an immunosuppressant. The compound is for research use only and is not intended for human therapeutic use. Its safety profile has not been extensively characterized.
|
| References |
Jansen Of Lorkeers SJ, Hart E, Tang XL, Chamuleau ME, Doevendans PA, Bolli R, Chamuleau SA. Cyclosporin in cell therapy for cardiac regeneration. J Cardiovasc Transl Res. 2014 Jul;7(5):475-82. doi: 10.1007/s12265-014-9570-8. Epub 2014 May 16.
|
| Additional Infomation |
Reports indicate that Trichoderma polysporum contains Cyclosporine B, and relevant data is available for reference.
Cyclosporin B is a minor analogue of the cyclosporin complex. It has a CAS number of 63775-95-1. It is an immunosuppressant. It is not approved for clinical use. |
| Molecular Formula |
C61H109N11O12
|
|---|---|
| Molecular Weight |
1188.60
|
| Exact Mass |
1187.825
|
| CAS # |
63775-95-1
|
| Related CAS # |
63775-95-1;
|
| PubChem CID |
12797522
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
1289.7±65.0 °C at 760 mmHg
|
| Melting Point |
149-152ºC
|
| Flash Point |
733.8±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.468
|
| LogP |
2.82
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
84
|
| Complexity |
2310
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
N1(C)[C@@]([H])([C@H](O)[C@H](C)C/C=C/C)C(=O)N[C@@H](C)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C1=O
|
| InChi Key |
UCOQITKXMNKTKF-MXGZYYNMSA-N
|
| InChi Code |
InChI=1S/C61H109N11O12/c1-25-26-27-39(14)51(74)50-55(78)64-41(16)56(79)66(18)32-47(73)67(19)43(28-33(2)3)54(77)65-48(37(10)11)60(83)68(20)44(29-34(4)5)53(76)62-40(15)52(75)63-42(17)57(80)69(21)45(30-35(6)7)58(81)70(22)46(31-36(8)9)59(82)71(23)49(38(12)13)61(84)72(50)24/h25-26,33-46,48-51,74H,27-32H2,1-24H3,(H,62,76)(H,63,75)(H,64,78)(H,65,77)/b26-25+/t39-,40+,41+,42-,43+,44+,45+,46+,48+,49+,50+,51-/m1/s1
|
| Chemical Name |
(3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28,30-decamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~84.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.8413 mL | 4.2066 mL | 8.4133 mL | |
| 5 mM | 0.1683 mL | 0.8413 mL | 1.6827 mL | |
| 10 mM | 0.0841 mL | 0.4207 mL | 0.8413 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA